Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells

Katri M. Koli, Timothy T. Ramsey, Yong Ko, Teresa C. Dugger, Michael G Brattain, Carlos L. Arteaga

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We have studied the role of autocrine transforming growth factor-β (TGF-β) signaling on antiestrogen-mediated growth inhibition of hormone- dependent T47D and MCF-7 human breast carcinoma cells. Tamoxifen treatment increased the secretion of TGF-β activity into serum-free cell medium and the cellular content of affinity cross-linked type I and III TGF-β receptors in both cell lines. Anti-pan-TGF-β antibodies did not block anti-estrogen- induced recruitment in G1 and inhibition of anchorage-dependent and - independent growth of both cell lines. Early passage MCF-7 cells, which exhibit detectable type II TGF-β receptors at the cell surface and exquisite sensitivity to exogenous TGF-β1, were transfected with a tetracycline- controllable dominant-negative TGF-βRII (ΔRII) construct. Although the TGF- β1 response was blocked by removal of tetracycline in MCF-7/ΔRII cells, tamoxifen-mediated suppression of Rb phosphorylation, recruitment in G1, and inhibition of cell proliferation were identical in the presence and absence of tetracycline. TGF-β1 treatment up-regulated the Cdk inhibitor p21 and induced its association with Cdk2 in MCF-7 cells; these responses were blocked by the ΔRII transgene product. In MCF-7 cells with a functional TGF- β signaling pathway, tamoxifen did not up-regulate p21 nor did it induce association of p21 with Cdk2, suggesting alternative mechanisms for antiestrogen-mediated cytostasis. Finally, transfection of late-passage, TGF- β1 unresponsive MCF-7 cells with high levels of TGF-βRII restored TGF-β1- induced growth inhibition but did not enhance tamoxifen response in culture. Taken together these data strongly argue against any role for TGF-β signaling on tamoxifen-mediated growth inhibition of hormone-dependent breast cancer cells.

Original languageEnglish (US)
Pages (from-to)8296-8302
Number of pages7
JournalJournal of Biological Chemistry
Volume272
Issue number13
DOIs
StatePublished - Mar 28 1997

Fingerprint

Estrogen Receptor Modulators
Transforming Growth Factors
Cells
Breast Neoplasms
Growth
MCF-7 Cells
Tamoxifen
Tetracycline
Growth Factor Receptors
Growth Hormone
Association reactions
Hormones
Cell Line
Phosphorylation
Serum-Free Culture Media
Cell proliferation
Transgenes
Transfection

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. / Koli, Katri M.; Ramsey, Timothy T.; Ko, Yong; Dugger, Teresa C.; Brattain, Michael G; Arteaga, Carlos L.

In: Journal of Biological Chemistry, Vol. 272, No. 13, 28.03.1997, p. 8296-8302.

Research output: Contribution to journalArticle

Koli, Katri M. ; Ramsey, Timothy T. ; Ko, Yong ; Dugger, Teresa C. ; Brattain, Michael G ; Arteaga, Carlos L. / Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. In: Journal of Biological Chemistry. 1997 ; Vol. 272, No. 13. pp. 8296-8302.
@article{98ecdb8bb0de42d1867a279d5dad83a8,
title = "Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells",
abstract = "We have studied the role of autocrine transforming growth factor-β (TGF-β) signaling on antiestrogen-mediated growth inhibition of hormone- dependent T47D and MCF-7 human breast carcinoma cells. Tamoxifen treatment increased the secretion of TGF-β activity into serum-free cell medium and the cellular content of affinity cross-linked type I and III TGF-β receptors in both cell lines. Anti-pan-TGF-β antibodies did not block anti-estrogen- induced recruitment in G1 and inhibition of anchorage-dependent and - independent growth of both cell lines. Early passage MCF-7 cells, which exhibit detectable type II TGF-β receptors at the cell surface and exquisite sensitivity to exogenous TGF-β1, were transfected with a tetracycline- controllable dominant-negative TGF-βRII (ΔRII) construct. Although the TGF- β1 response was blocked by removal of tetracycline in MCF-7/ΔRII cells, tamoxifen-mediated suppression of Rb phosphorylation, recruitment in G1, and inhibition of cell proliferation were identical in the presence and absence of tetracycline. TGF-β1 treatment up-regulated the Cdk inhibitor p21 and induced its association with Cdk2 in MCF-7 cells; these responses were blocked by the ΔRII transgene product. In MCF-7 cells with a functional TGF- β signaling pathway, tamoxifen did not up-regulate p21 nor did it induce association of p21 with Cdk2, suggesting alternative mechanisms for antiestrogen-mediated cytostasis. Finally, transfection of late-passage, TGF- β1 unresponsive MCF-7 cells with high levels of TGF-βRII restored TGF-β1- induced growth inhibition but did not enhance tamoxifen response in culture. Taken together these data strongly argue against any role for TGF-β signaling on tamoxifen-mediated growth inhibition of hormone-dependent breast cancer cells.",
author = "Koli, {Katri M.} and Ramsey, {Timothy T.} and Yong Ko and Dugger, {Teresa C.} and Brattain, {Michael G} and Arteaga, {Carlos L.}",
year = "1997",
month = "3",
day = "28",
doi = "10.1074/jbc.272.13.8296",
language = "English (US)",
volume = "272",
pages = "8296--8302",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells

AU - Koli, Katri M.

AU - Ramsey, Timothy T.

AU - Ko, Yong

AU - Dugger, Teresa C.

AU - Brattain, Michael G

AU - Arteaga, Carlos L.

PY - 1997/3/28

Y1 - 1997/3/28

N2 - We have studied the role of autocrine transforming growth factor-β (TGF-β) signaling on antiestrogen-mediated growth inhibition of hormone- dependent T47D and MCF-7 human breast carcinoma cells. Tamoxifen treatment increased the secretion of TGF-β activity into serum-free cell medium and the cellular content of affinity cross-linked type I and III TGF-β receptors in both cell lines. Anti-pan-TGF-β antibodies did not block anti-estrogen- induced recruitment in G1 and inhibition of anchorage-dependent and - independent growth of both cell lines. Early passage MCF-7 cells, which exhibit detectable type II TGF-β receptors at the cell surface and exquisite sensitivity to exogenous TGF-β1, were transfected with a tetracycline- controllable dominant-negative TGF-βRII (ΔRII) construct. Although the TGF- β1 response was blocked by removal of tetracycline in MCF-7/ΔRII cells, tamoxifen-mediated suppression of Rb phosphorylation, recruitment in G1, and inhibition of cell proliferation were identical in the presence and absence of tetracycline. TGF-β1 treatment up-regulated the Cdk inhibitor p21 and induced its association with Cdk2 in MCF-7 cells; these responses were blocked by the ΔRII transgene product. In MCF-7 cells with a functional TGF- β signaling pathway, tamoxifen did not up-regulate p21 nor did it induce association of p21 with Cdk2, suggesting alternative mechanisms for antiestrogen-mediated cytostasis. Finally, transfection of late-passage, TGF- β1 unresponsive MCF-7 cells with high levels of TGF-βRII restored TGF-β1- induced growth inhibition but did not enhance tamoxifen response in culture. Taken together these data strongly argue against any role for TGF-β signaling on tamoxifen-mediated growth inhibition of hormone-dependent breast cancer cells.

AB - We have studied the role of autocrine transforming growth factor-β (TGF-β) signaling on antiestrogen-mediated growth inhibition of hormone- dependent T47D and MCF-7 human breast carcinoma cells. Tamoxifen treatment increased the secretion of TGF-β activity into serum-free cell medium and the cellular content of affinity cross-linked type I and III TGF-β receptors in both cell lines. Anti-pan-TGF-β antibodies did not block anti-estrogen- induced recruitment in G1 and inhibition of anchorage-dependent and - independent growth of both cell lines. Early passage MCF-7 cells, which exhibit detectable type II TGF-β receptors at the cell surface and exquisite sensitivity to exogenous TGF-β1, were transfected with a tetracycline- controllable dominant-negative TGF-βRII (ΔRII) construct. Although the TGF- β1 response was blocked by removal of tetracycline in MCF-7/ΔRII cells, tamoxifen-mediated suppression of Rb phosphorylation, recruitment in G1, and inhibition of cell proliferation were identical in the presence and absence of tetracycline. TGF-β1 treatment up-regulated the Cdk inhibitor p21 and induced its association with Cdk2 in MCF-7 cells; these responses were blocked by the ΔRII transgene product. In MCF-7 cells with a functional TGF- β signaling pathway, tamoxifen did not up-regulate p21 nor did it induce association of p21 with Cdk2, suggesting alternative mechanisms for antiestrogen-mediated cytostasis. Finally, transfection of late-passage, TGF- β1 unresponsive MCF-7 cells with high levels of TGF-βRII restored TGF-β1- induced growth inhibition but did not enhance tamoxifen response in culture. Taken together these data strongly argue against any role for TGF-β signaling on tamoxifen-mediated growth inhibition of hormone-dependent breast cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0030967476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030967476&partnerID=8YFLogxK

U2 - 10.1074/jbc.272.13.8296

DO - 10.1074/jbc.272.13.8296

M3 - Article

VL - 272

SP - 8296

EP - 8302

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -